Literature DB >> 19708997

C-reactive protein and uremia.

Christoph Wanner1, Christiane Drechsler, Vera Krane.   

Abstract

Since the first report of elevated serum levels of C-reactive protein (CRP) predicting all cause and cardiovascular mortality more than 10 years ago, many other studies have recognized that the uremic milieu is associated with a state of chronic inflammation. The causes for inflammation are multiple and have been well studied in the past 10 years. Nondialysis, uremia related and endogenous factors as well as the dialysis procedure itself may be responsible for the high prevalence of inflammation in dialysis patients. Today, CRP serves to improve overall vascular risk stratification and, in the individual, to detect sources of specific infections. Because multiple factors contribute to the milieu of inflammation, the predictive value of CRP is rather nonspecific in dissecting a cause, with respect to the subcomponents of cardiac, vascular, and even noncardiovascular causes of mortality. So far, no specific pharmacologic treatment, including atorvastatin, has been identified that can substantially reduce CRP and accompanying inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708997     DOI: 10.1111/j.1525-139X.2009.00596.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  9 in total

1.  Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Christopher W McIntyre; Laura E A Harrison; M Tarek Eldehni; Helen J Jefferies; Cheuk-Chun Szeto; Stephen G John; Mhairi K Sigrist; James O Burton; Daljit Hothi; Shvan Korsheed; Paul J Owen; Ka-Bik Lai; Philip K T Li
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

2.  Evidence for anti-inflammatory effects of exercise in CKD.

Authors:  João L Viana; George C Kosmadakis; Emma L Watson; Alan Bevington; John Feehally; Nicolette C Bishop; Alice C Smith
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

Review 3.  Noncardiovascular mortality in CKD: an epidemiological perspective.

Authors:  Dinanda J de Jager; Marc G Vervloet; Friedo W Dekker
Journal:  Nat Rev Nephrol       Date:  2014-02-04       Impact factor: 28.314

4.  Endotoxemia is associated with acute coronary syndrome in patients with end stage kidney disease.

Authors:  Chien-Chin Hsu; Tsui-Shan Wei; Chien-Cheng Huang; Yi-Ming Chen
Journal:  BMC Nephrol       Date:  2017-07-12       Impact factor: 2.388

5.  Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluation of inflammation in non-dialysis patients with end-stage renal disease (ESRD).

Authors:  Peiyuan Li; Chenqi Xia; Peng Liu; Zhong Peng; Hong Huang; Juan Wu; Zhangxiu He
Journal:  BMC Nephrol       Date:  2020-11-25       Impact factor: 2.388

6.  Endotoxin binding by sevelamer: potential impact on nutritional status.

Authors:  Natsuki Kubotera; Alexander J Prokopienko; Adinoyi O Garba; Amy Barton Pai
Journal:  Int J Nephrol       Date:  2013-01-17

7.  High-sensitivity C-reactive protein predicts mortality and technique failure in peritoneal dialysis patients.

Authors:  Shou-Hsuan Liu; Yi-Jung Li; Hsin-Hsu Wu; Cheng-Chia Lee; Chan-Yu Lin; Cheng-Hao Weng; Yung-Chang Chen; Ming-Yang Chang; Hsiang-Hao Hsu; Ji-Tseng Fang; Cheng-Chieh Hung; Chih-Wei Yang; Ya-Chung Tian
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

8.  Nutritional Predictors of Mortality in Long Term Hemodialysis Patients.

Authors:  Cheng-Hao Weng; Ching-Chih Hu; Tzung-Hai Yen; Ching-Wei Hsu; Wen-Hung Huang
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

9.  The value of time-averaged serum high-sensitivity C-reactive protein in prediction of mortality and dropout in peritoneal dialysis patients.

Authors:  Shou-Hsuan Liu; Chao-Yu Chen; Yi-Jung Li; Hsin-Hsu Wu; Chan-Yu Lin; Yung-Chang Chen; Ming-Yang Chang; Hsiang-Hao Hsu; Cheng-Lung Ku; Ya-Chung Tian
Journal:  Ther Clin Risk Manag       Date:  2017-08-16       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.